

CLAIMS

1. Use of angelicin or a structural analogue thereof for the preparation of a medicament for the therapeutic treatment of beta-thalassaemia.
2. Use according to claim 1, wherein the structural analogue is selected from the group consisting of linear and angular coumarins, optionally substituted, heteroanalogues of angelicin, thiopyrano-benzofurans, acylangelicins, alkyangelicins, alkoxycarbamoyl angelicins, psoralens, and isop-soralens, optionally substituted.
3. Use according to claim 2, wherein the structural analogue is bergapten.
4. Use according to any one of the preceding claims wherein the angelicin or structural analogue is in combination with at least one further modifier of the transcription process.
5. Use according to Claim 4 in which the further modifier of the transcription process is selected from the group consisting of cytosine arabinoside, retinoic acid, plicamycin, mithramycin, hydroxyurea, guanine, guanosine triphosphate (GTP), guanosine diphosphate (GDP) and guanosine monophosphate (GMP).